中文

Hong Kong Stocks · Free Data Page

PHARMARON 03759

PHARMARON: FY2025 revenue CN¥14.10B (+14.80% YoY); net income CN¥1.66B; 0 alerts, 3 watch items out of 17 risk checks; TTM dividend HK$0.23/sh.
Close PriceHK$29.38Day +13.00%Market CapHK$53.92BP/E26.4xTTMP/B2.74xDividend Yield0.78%TTMROE (FY2025)11.6%Avg. equity

Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.

Want the full AI research report for PHARMARON?

This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.

New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.

10-Year FinancialsFY2016–2025

Financial statements are reported in CNY, while share price and market cap are quoted in HKD.

Key Multi-Year Facts

  • Revenue moved from CN¥1.63B in FY2016 to CN¥14.10B in FY2025 (9-year CAGR +27.0%).
  • Profitable in every fiscal year across 2016–2025.

Latest 5 Fiscal Years

Fiscal Year20212022202320242025
Revenue (CNY B)7.4410.311.512.314.1
YoY45.0%37.9%12.4%6.4%14.8%
Net Income (CNY B)1.661.371.601.791.66
YoY41.7%-17.2%16.5%12.0%-7.2%
Operating Cash Flow (CNY B)2.062.142.752.583.22
ROE17.5%13.3%—13.2%11.6%
Gross Margin35.9%36.5%35.5%33.8%34.5%
Net Margin22.3%13.4%13.9%14.6%11.8%
Debt-to-Assets44.0%47.1%—40.6%41.9%
Show all 10 fiscal years
Fiscal Year2016201720182019202020212022202320242025
Revenue (CNY B)1.632.292.913.765.137.4410.311.512.314.1
YoY—40.4%26.8%29.2%36.6%45.0%37.9%12.4%6.4%14.8%
Net Income (CNY B)0.170.220.340.551.171.661.371.601.791.66
YoY—29.9%51.0%62.8%114.3%41.7%-17.2%16.5%12.0%-7.2%
Operating Cash Flow (CNY B)0.260.590.790.941.652.062.142.752.583.22
ROE9.7%11.9%15.6%10.9%14.1%17.5%13.3%—13.2%11.6%
Gross Margin30.5%33.8%32.6%35.4%37.3%35.9%36.5%35.5%33.8%34.5%
Net Margin10.5%9.7%11.6%14.6%22.8%22.3%13.4%13.9%14.6%11.8%
Debt-to-Assets39.6%51.8%51.6%21.1%25.0%44.0%47.1%—40.6%41.9%

Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings

Risk ChecklistAs of 2026-11-05

Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).

0Alert 3Watch 14Pass

Items Flagged for Review

  • Watch

    GoodwillFinancial Quality

    CN¥3.48B, 20.6% of equity

    Q3 (2026-09-30) · What is this?

  • Watch

    Short-Term Debt CoverageSolvency

    Cash CN¥3.01B, short-term debt CN¥4.79B (0.63x)

    Q3 (2026-09-30) · What is this?

  • Watch

    Profit WarningMaterial Events

An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.

Dividends

Trailing 12-month dividend: HK$0.229 per share, or 0.78% yield at closing price; last full fiscal year: HK$0.229 (payout ratio 21.0%).

Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.

More data: All research reports · Sector leaders · Market hours & holidays.

Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.